Episodes

States have begun to release their vaccine distribution plans, and President Trump and Biden spent the final debate sparring over the vaccine delivery timeline. The media says conflicting things. What should you believe, and ...

Drug pricing continues to make the news, so we’re revisiting our conversation with Dr. Janet Woodcock of the FDA about bringing drug manufacturing back to the U.S. Hear how American-made drugs might lower costs and improve ov...

President Trump’s apparent quick and successful battle with the COVID-19 virus should set the standard for care that all Americans should receive. Terry and Dr. Bob look at how the White House is grappling with spreading infe...

The future of the Affordable Care Act is uncertain with a Supreme Court vacancy. Terry and Dr. Bob discuss protections for preexisting conditions, and Congressman Michael Burgess speaks on the need for price transparency and ...

Cancer research may yield a potential COVID-19 therapeutic. Dr. Bob interviews Dr. John Rothman of Tyme Technologies about the promising preclinical studies for a new therapeutic. Plus, Kate speaks with Michelle Whitlock, a t...

The finish line for the vaccine race is just around the corner. Terry and Dr. Bob react to vaccine developments and respond to ICER’s recent attacks. Plus, the second part of our interview with Dr. Robert Popovian gives us th...

Get an inside look into the drug supply chain and the factors that impact your bill at the pharmacy counter. Dr. Robert Popovian, VP of Government Relations at Pfizer, joins Terry to discuss how benefit design and rebates imp...

In celebration of Labor Day, we look at a business that is empowering the chronic disease community. Kate interviews Keisha Greaves, founder of the clothing brand Girls Chronically Rock. Plus, Terry and Dr. Bob discuss a pote...

The lives of chronic and rare disease patients depend on the progress of medical discoveries. Dr. Gary Michelson explains how investment in innovative, high-risk research will improve patient outcomes. Plus hear from Lindsey ...

ICER’s pricing models assess the value of a drug and whether your life is worth paying for it. Health economist Dr. Paul Langley explains how ICER’s recommendations devalue patient lives and create barriers to accessible trea...

With a vaccine still months away, Americans with chronic disease are adapting to life with COVID-19. Dr. Paul Offit returns to discuss the status of a vaccine and living with the risk of infection. Terry and Bob consider scho...

Patients deserve easy access to their medical records. With digital healthcare solutions on the rise, new companies are providing patient-centric solutions to gather, own, and share personal health data. Dr. Bob speaks with S...

President Trump’s recent executive orders are a move to lower prescription drug prices for patients. But what changes should patients expect to see? We talk to the former lead health advisor to President Trump, Katy Talento, ...

Value-based healthcare models are a way to improve patient outcomes and lower the cost of care. Dr. Bob speaks with former FDA and CMS chief Dr. Mark McClellan, who says the pandemic has shown the benefits of value-based care...

Despite interruptions due to COVID-19, Congress continues working to address health disparities, chronic disease, and relief for coronavirus. Terry interviews Congressman Fred Upton, co-author of the 21st Century Cures Act, t...

Can technology improve healthcare, even without the in-person relationship? Telemedicine has seen an explosion of utilization due to the pandemic. On this episode, we explore the countless new technologies that are changing h...

At the pharmacy counter, patients are often surprised by mysterious high costs, due to pharmaceutical benefit managers (PBMs). These middlemen lead to inconsistent and unclear prices, making it difficult for chronic disease p...

COVID-19 has hit minority populations particularly hard, delivering a wake-up call to healthcare policymakers. How can we change the system to help marginalized communities get access to the care they need? Dr. Bob speaks wit...

Patients with rare diseases may soon have better access to treatments. A second installment to the 21st Century Cures Act is in the works that would make improvements to telemedicine and digital health regulations. Find out w...

Made in the USA: The return of drug manufacturing to the U.S. could help improve drug safety, cost, and accessibility for patients with chronic disease. Dr. Janet Woodcock is director of the FDA’s Center for Drug Evaluation a...

A victory for patients in Oklahoma as the state bans a discriminatory healthcare metric. Quality-adjusted-life-years (QALYs) are used by numerous insurance companies to block coverage based on disability or age. Two mothers o...

Higher quality care at lower prices might be possible. Some companies are harnessing the power of anonymous, patient data to improve patient protocols and replace pharmacy benefit managers. Dr. Bob sits down with two leaders ...

What will this cost? It’s the big question when it comes to healthcare, and it’s often impossible to answer. Health care policy expert David Balat explains how transparent pricing models put patients in control of their healt...

The nation is focused on development of a COVID-19 vaccine. And there’s conflicting information from all sides. For those with chronic illnesses, a vaccine will be even more critical if they hope to return to offices and cli...